Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections
|
|
- Ginger Stokes
- 5 years ago
- Views:
Transcription
1 International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections David A. Talan a,, Kurt G. Naber b, Juan Palou c, David Elkharrat d a Department of Medicine, Divisions of Infectious Diseases and Emergency Medicine, Olive View-UCLA Medical Center, Olive View Drive, North Annex, Sylmar, CA 91342, USA b Urologic Clinic, Hospital St. Elisabeth, Straubing, Germany c Department of Urology and Pharmacy, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain d Hopital Lariboisiere, Paris, France Abstract Symptomatic urinary tract infections (UTIs) constitute a major health problem throughout the Western world. In the USA, UTIs are responsible for 7 8 million outpatient visits each year and for over one-third of all hospital-acquired infections. Empiric antimicrobial therapy for UTIs, which are primarily caused by Escherichia coli, is increasingly being complicated by the emergence of resistance to the most widely used agents. Recent studies indicate that the prevalence of E. coli resistance to trimethoprim/sulphamethoxazole (TMP/SMX), the current first-line therapy for UTIs, exceeds 20% in many North American regions. Importantly, antibiotic resistance often translates into clinical failure. The use of antibiotics with favourable pharmacokinetic/pharmacodynamic profiles and convenient dosing schedules, which effectively increase bacterial eradication and patient compliance, can help to curb the current epidemic of resistance and reduce the rate of clinical failure associated with resistance. Fluoroquinolones have well-established efficacy in the treatment of multiple bacterial infections and, over the years, the rates of resistance to these antibiotics have remained very low. Fluoroquinolones are currently recommended for therapy of uncomplicated UTIs when the local incidence of TMP/SMX resistance is 10 20%, as well as for the treatment of complicated UTIs and acute pyelonephritis. Ciprofloxacin, one of the most widely used fluoroquinolones, has a potent bactericidal effect across the full spectrum of uropathogens, as well as a long and excellent efficacy and safety record in the management of UTI and other infections. A recently developed extended (modified)-release formulation of ciprofloxacin (Cipro XR or Cipro XL) provides higher maximum plasma concentrations with lower inter-patient variability than the conventional, immediate-release, twice-daily formulation. Additionally, therapeutic drug levels with extended-release ciprofloxacin are achieved rapidly and maintained over the course of 24 h, allowing once-daily dosing. Clinical trials in patients with cystitis and those with complicated UTIs or acute uncomplicated pyelonephritis indicate that extended-release ciprofloxacin is at least as effective as the immediate-release formulation. These studies have also confirmed good tolerability and safety of extended-release ciprofloxacin, similar to the immediate-release formulation. Therefore, extended-release ciprofloxacin is a convenient, well-tolerated and effective therapy for UTIs that may improve patients compliance with treatment and thus decrease the risk of treatment failure and the spread of antibiotic resistance Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. Keywords: Ciprofloxacin; Urinary tract infections; Trimethoprim/sulphamethoxazole 1. Introduction Urinary tract infections (UTIs) are among the most prevalent infectious diseases, and their financial burden on society is substantial. In the USA, UTIs are responsible for over 7 million physician visits annually, including >2 million visits for cystitis [1,2]. In addition, UTIs account for more Corresponding author. Tel.: ; fax: address: dtalan@ucla.edu (D.A. Talan). than 100,000 hospital admissions annually, most often for pyelonephritis [1,2], and they also comprise over one-third of all hospital-acquired infections [3]. Approximately 15% of all community-prescribed antibiotics in the USA are dispensed for UTI, at an estimated annual cost of over US$ 1 billion [4]. Furthermore, the direct and indirect costs associated with community-acquired UTIs in the USA alone exceed US$ 1.6 billion [2]. Women are particularly at high risk for the development of UTIs. In the USA, 10.8% of women over 18 years of age experience at least one UTI each year [2,5]. By age of /$ see front matter 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. doi: /j.ijantimicag
2 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 S55 years, about one-third of women will have had one or more UTIs requiring antibiotic treatment, and nearly one-half of women will have a UTI at some point during their lives [2,6] Remarkably, the risk for UTIs among women between 16 and 35 years of age is approximately 40 times that for men [4]. The bacterial aetiology of UTI is well established, with at least 80% of community-acquired, uncomplicated cases being caused by Escherichia coli [1,7 9]. Other important uropathogens include Staphylococcus saprophyticus (almost exclusively in younger women with cystitis), Klebsiella spp., Proteus mirabilis and other Enterobacteriaceae [1,7 9]. Complicated UTIs, including those in catheterised patients, are frequently associated with enterococci and other Gram-positive species [4]. Management of UTIs has been complicated by the emergence of resistance to most commonly used antibiotics. Increasing prevalence of resistance has led to a gradual evolution in the antibiotics used to treat UTIs. Until the 1990s, the -lactam, ampicillin, was the most widely prescribed therapy for UTIs, but the high rates of E. coli resistance to this antibiotic (typically resulting from expression of -lactamase) [10], prompted a switch to trimethoprim/sulphamethoxazole (TMP/SMX), which was subsequently considered the first-line treatment for these infections. However, broad use of TMP/SMX has also resulted in high rates of resistance to this therapy among uropathogens. Surveillance results for Canada and the US indicate that 18 25% of E. coli isolates from outpatients with acute uncomplicated UTI are now resistant to TMP/SMX [6]. The rates are even higher among nosocomial isolates in Europe (33%) and Latin America (45%) [10]. This increase in resistance with wider use of TMP/SMX is highly reminiscent of the previous situation with ampicillin and underscores the need to re-evaluate and optimise first-line therapy of UTI. The fluoroquinolones are well-established broad-spectrum antibiotics with potent bactericidal activity against clinically important pathogens responsible for a variety of infections, including UTIs, gastrointestinal (GI) infections, respiratory tract infections, sexually transmitted diseases, skin infections and chronic osteomyelitis [13,14]. This large class of agents is characterised by a favourable pharmacokinetic profile, with high tissue penetration and rapid bactericidal action. The clinical value of fluoroquinolones in the management of UTIs has been recognised by the guidelines developed by the Infectious Diseases Society of America (IDSA) [1] and the European Association of Urology (EAU) [15], both of which recommend the use of these agents in areas where the local prevalence of TMP/SMX resistance is 10 20%. Notably, a recent analysis has revealed that the prevalence of E. coli resistant to TMP/SMX among women with community-acquired UTI is over 10% in each of the nine United States Census Bureau regions [12]. Moreover, the TMP/SMX resistance rates among uropathogenic E. coli isolates from women with community-acquired UTI in various western European countries also exceed 10%, as reviewed by Gupta et al. [16]. Ciprofloxacin became the first widely available fluoroquinolone antibiotic in the second half of the 1980s. This drug has potent bactericidal activity against a broad range of clinically relevant Gram-negative and Gram-positive pathogens, and it has been effectively used to treat a variety of bacterial infections, including UTIs, sexually transmitted infections, gastrointestinal infections, as well as skin and bone infections [13,17]. Importantly, in contrast to the dramatic increases in resistance of uropathogens to ampicillin and TMP/SMX, the resistance to ciprofloxacin has remained low [10 12,18,19]. In a recent surveillance study of urinary E. coli isolates from outpatient women in the USA, collected during the year 2000, the rates of ampicillin and TMP/SMX susceptibility (59.9 and 75.7%, respectively) were far lower than the susceptibility to ciprofloxacin (96.4%) [11]. Similar findings were reported in the analysis of 16,745 E. coli isolates from female outpatients with UTI collected in the Pacific region of the USA in 2001 (ampicillin resistance: 38.0%; TMP/SMX resistance: 20.3%; ciprofloxacin resistance: 2.3%) [12]. The SENTRY Antimicrobial Surveillance Program for the year 2000 also demonstrated that the susceptibility of uropathogenic E. coli isolated from hospitalised patients with UTI is far greater for ciprofloxacin than for either ampicillin or TMP/SMX, across all geographic regions evaluated (North America, Europe, Latin America) [10]. For example, in North America, 95% of E. coli isolates were susceptible to ciprofloxacin, whereas the susceptibility rates for ampicillin and TMP/SMX were only 62 and 77%, respectively [10]. The importance of very high susceptibility rates to ciprofloxacin in the management of UTIs is underscored by several recent reports [16,20 23], which have documented increasing prevalence of clinical failure in areas with high levels of TMP/SMX resistance. These findings further support the IDSA and EAU guidelines recommendations for the use of fluoroquinolones in regions where local prevalence of TMP/SMX resistance is 10 20% [1,15]. Until recently, oral ciprofloxacin has been available only as conventional, immediate-release tablets that required twice-daily administration. An extended (modified)-release ciprofloxacin (Cipro XR or Cipro XL), which provides both a fast-acting and convenient once-daily alternative to the standard, immediate-release, twice-daily tablets, has now been developed [24]. Taking into account the declining effectiveness of TMP/SMX [10] and the recognition that many patients with UTIs require alternative antimicrobial therapy [1,15], the availability of extended-release ciprofloxacin as an effective, well-tolerated and more convenient alternative to conventional ciprofloxacin, is particularly timely. Extended-release ciprofloxacin therefore provides clinicians with a new treatment option that may enhance patient adherence to treatment and thereby improve clinical success rates. The goal of this review is to describe the impact of increasing prevalence of TMP/SMX resistance on clinical
3 S56 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 outcomes in UTIs and, in this context, discuss the clinical role of extended-release ciprofloxacin, focusing on its pharmacologic and clinical profile versus the conventional, immediate-release, bid ciprofloxacin. 2. The impact of pathogen resistance on clinical outcomes in patients with UTIs 2.1. Pathogens associated with UTIs The prevalence of specific UTI-associated micro-organisms varies geographically, but E. coli is the most common pathogen, typically being isolated from over 80% of outpatients with acute uncomplicated cystitis across the various regions of the world [16]. S. saprophyticus accounts for 5 15% of these infections and is especially prevalent in younger women with cystitis. Causative pathogens in the remaining 5 10% of cases include aerobic Gram-negative rods, such as Klebsiella and Proteus spp. and other enterococci [10,16]. The range of pathogens associated with acute uncomplicated pyelonephritis is similar to that seen in acute uncomplicated cystitis [20,25] Patterns of antibiotic resistance to TMP/SMX Although TMP/SMX has been the cornerstone of UTI therapy over the past 20 years, results from a large number of surveillance studies and clinical trials have demonstrated a significant upward trend in TMP/SMX resistance among major uropathogens, most notably E. coli. For example, in the 5-year period from 1992 to 1996, the percentage of E. coli resistant to TMP/SMX in Seattle, Washington, increased from 9 to 18% in women with acute uncomplicated cystitis [26]. More recent studies have documented a further increase in TMP/SMX resistance in both community acquired and nosocomial E. coli isolates collected from 1997 to 2001 in North America [10 12,18,27,28]. Within the USA, the prevalence of TMP/SMX-resistant E. coli among outpatient females with UTI in 2001 exceeded 10% in all nine Census Bureau regions, and the highest rates were observed in the Pacific and west south central regions (20.3 and 21.8%, respectively) [12]. In addition, TMP/SMX resistance has been shown to be even higher (>25%) among uropathogens isolated from outpatients with UTI in Spain ( ) [29], Israel ( ) [23] and the UK ( ) [19]. Additionally, the prevalence of TMP/SMX-resistant E. coli isolates among hospitalised patients with UTI during the year 2000 ranged from 23% in North America to 33% in Europe to 45% in Latin America [10]. Extensive use of TMP/SMX has been demonstrated to be a major driver of TMP/SMX resistance among urinary pathogens. In a study by Wright et al., which retrospectively assessed factors associated with pathogen resistance in 448 emergency department outpatients with UTIs, a multivariate logistic regression analysis identified recent TMP/SMX use (odds ratio: 5.1; 95% confidence intervals (CI): ) and current antimicrobial use (odds ratio: 4.5; 95% CI: ) as the two strongest predictors of TMP/SMX resistance [30]. These findings were confirmed more recently by Steinke et al., who demonstrated that prior TMP use was the most powerful factor associated with TMP/SMX resistance (adjusted odds ratio: 3.81; 95% CI: ) [31]. Collectively, these findings are consistent with the hypothesis that the high use of TMP/SMX is a major cause of antibiotic resistance among pathogens responsible for UTIs Resistance to fluoroquinolones In contrast to TMP/SMX, the resistance to which has markedly increased over the past 10 years, ciprofloxacin has continued to exhibit potent bactericidal activity against the pathogens most often associated with UTIs [10,27,28,32,33]. Surveillance studies in hospital and community settings have shown that only a small percentage of E. coli isolates from patients with UTIs shows resistance to this fluoroquinolone, and that resistance rates have not risen substantially over the last several years. In a study conducted in the UK, using samples collected from outpatients and hospitalised patients with UTIs in 1999 and 2000, over 97% of E. coli isolates were susceptible to ciprofloxacin [19]. Karlowsky et al. have assessed the prevalence of ciprofloxacin resistance in over 250,000 E. coli isolates from female outpatients with UTIs in the US in the period between 1995 and 2001, demonstrating only a modest increase in resistance over this 7-year period (from 0.7 to 2.5%, respectively) [12]. Additionally, the comparison of resistance rates to ciprofloxacin and TMP/SMX in over 350,000 E. coli isolates collected from female outpatients with UTIs in the US between 1998 and 2001 shows substantially lower prevalence of resistance to ciprofloxacin (2.3% versus 17.5% for TMP/SMX) [18]. Moreover, in a European survey, over 93% of 1927 uropathogenic E. coli isolates from outpatients with UTI were susceptible to ciprofloxacin (MIC 1 mg/l), with little variability across individual countries [34]. Similar findings were also reported in a separate study of 2478 uropathogenic E. coli isolates from female outpatients with UTI in European countries and Canada (ciprofloxacin resistance: 2.3%), although in Spain, where the incidence of TMP/SMX resistance is very high (25.7%), the incidence of ciprofloxacin resistance was higher (14.7%) [29]. This maintenance of high activity of ciprofloxacin against E. coli and other uropathogens, including strains resistant to TMP/SMX, suggests that ciprofloxacin is likely to remain clinically and bacteriologically effective therapy in patients with UTIs Impact of pathogen resistance on clinical outcomes Several studies have clearly demonstrated that resistance to TMP/SMX can result in bacteriologic and clinical failure in patients with UTIs. In one study of women with
4 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 S57 Table 1 Clinical and bacteriologic success of trimethoprim/sulphamethoxazole (TMP/SMX) at 5 9 days in women with urinary tract infections treated with this therapy according to the pathogens susceptibility to TMP/SMX (adapted with permission from Raz et al. [23]) Parameter TMP/SMX-susceptible pathogens (%) TMP/SMX-resistant pathogens (%) P-value Clinical cure <0.001 Bacteriologic <0.001 cure acute uncomplicated UTIs, bacteriologic success rates with TMP/SMX (960 mg bid for 7 days) among patients infected with TMP/SMX-resistant pathogens was substantially lower than in the overall TMP/SMX cohort (50 and 86.2%, respectively), and clinical failure was significantly correlated with TMP resistance (P 0.05) [21]. Similar results were obtained in a study of 866 women with UTIs and positive urine cultures (81% infected with E. coli) who were randomised to 3 days of treatment with ciprofloxacin (100 mg bid), ofloxacin (200 mg bid), or TMP/SMX (960 mg bid) [22]. In this study, clinical and bacteriologic success rates with TMP/SMX were considerably lower among patients who had TMP/SMX-resistant uropathogens (60 and 50%, respectively) than in the overall population of patients receiving TMP/SMX (95 and 92.5%, respectively) [22]. Most recently, the strong correlation between TMP/SMX resistance and clinical failure in women with uncomplicated UTIs was corroborated by the results of a study conducted in Israel (Table 1), a region with high prevalence of TMP/SMX resistance (29%) [23]. A study by Talan et al., which compared the efficacy of ciprofloxacin (500 mg bid for 7 days) versus TMP/ SMX (960 mg bid for 14 days) in 255 women with acute pyelonephritis, confirms the association between TMP/ SMX resistance and clinical failure in patients with acute pyelonephritis and demonstrates excellent efficacy of ciprofloxacin in patients with TMP/SMX-resistant uropathogens [20]. In agreement with previously described studies in women with uncomplicated UTIs, clinical and bacteriologic success rates at the test-of-cure visit (4 11 days) among patients treated with TMP/SMX were substantially lower if the pathogens were resistant to this treatment (35 and 50%, respectively, versus 92 and 96%, respectively, in patients with TMP/SMX-susceptible isolates). Furthermore, in patients with TMP/SMX-resistant isolates, ciprofloxacin achieved very high rates of clinical cure and bacteriologic eradication (95 and 100%, respectively) [20]. Taken together with the results from studies in uncomplicated UTIs (see earlier), these findings underscore the need for alternative first-line therapies, such as fluoroquinolones, in areas with high prevalence of TMP/SMX resistance. This need is recognised in the most recent guidelines for treatment of UTIs developed by the IDSA [1] and the EAU [15], whose recommendations are summarised in Section Guidelines for the treatment of UTIs 3.1. IDSA guidelines The IDSA guidelines recommendations were based on the analyses of clinical trials of antimicrobial therapies in women with uncomplicated acute symptomatic bacterial cystitis or acute pyelonephritis, taking into account the local prevalence and clinical impact of TMP/SMX resistance [1]. According to the IDSA guidelines, use of a 3-day TMP/SMX regimen for treatment of acute uncomplicated cystitis may be considered in geographic areas where the rate of TMP/SMX-resistant E. coli is <20%, although the use of alternate first-line therapies, most notably fluoroquinolones, is recommended in regions in which the incidence of TMP/SMX resistance is 10 20% [1]. In outpatients with acute pyelonephritis, the IDSA guidelines recommend the use of a 7 14-day oral fluoroquinolone regimen, whereas TMP/SMX use should be reserved for those patients in whom the pathogenic isolates are known to be susceptible to this therapy [1]. This recommendation was subsequently supported by the results of the study by Talan et al., which showed that the use of TMP/SMX in patients with TMP/SMX-resistant pathogens dramatically increases the rate of clinical and bacteriologic failure, and that ciprofloxacin is highly active against TMP/SMX-resistant pathogens [20]. Parenteral fluoroquinolones (or aminoglycosides or extended-spectrum cephalosporins) are recommended for hospitalised patients with acute pyelonephritis, whereas no specific recommendations are made for treatment of recurrent, complicated or nosocomial urinary infections [1] EAU guidelines The EAU guidelines recommendations (Table 2) [15] are similar to those developed by the IDSA expert panel. For empiric treatment of acute uncomplicated cystitis, the EAU guidelines recommend the use of a 3-day regimen of TMP/SMX in regions where the incidence of TMP/SMX resistance is less than 10%, and a 3-day course of fluoroquinolone therapy in areas in which the prevalence of TMP/SMX resistance is 10 20% [15]. In patients with mild cases of acute, uncomplicated pyelonephritis, the EAU guidelines recommend 7 days of treatment with oral fluoroquinolones. For more severe cases of acute pyelonephritis, the EAU guidelines recommend hospitalisation and initial treatment with parenteral fluoroquinolones, with conversion to oral fluoroquinolones guided by symptom improvement [15]. The EAU guidelines also address treatment of complicated and nosocomial UTI, recommending the use of a fluoroquinolone, a -lactam, or an aminoglycoside for empiric therapy [15]. In addition, a variety of therapies, including ciprofloxacin, are recommended for prevention of recurrent UTI [15].
5 S58 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 Table 2 Recommendations for treatment of acute cystitis, acute pyelonephritis, and complicated urinary tract infections by the European Association of Urology Working Group (reproduced with permission from Naber et al. [15]) Diagnosis Most frequent pathogen Initial empiric antimicrobial therapy Duration of treatment Acute uncomplicated cystitis Acute uncomplicated pyelonephritis E. coli, Klebsiella, Proteus, Staphylococcus E. coli, Proteus, Klebsiella, other Enterobacteria, Staphylococcus Trimethoprim/sulphamethoxazole Fluoroquinolone Alternatives: Fosfomycin trometamol Pivmecillinam Nitrofurantoin Fluoroquinolone 3 days 3 days 1 day 7 days 7 days 7 10 days Cephalosporin Gr. 2/3a Alternatives: Aminopenicillin/BLI Aminoglycoside UTI with complicating factors E. coli, Enterococcus 3 5 days after defervescence or control/elimination of complicating factor Nosocomial UTI Staphylococcus, Klebsiella, Proteus Acute complicated pyelonephritis Enterobacter, other Enterobacteria, Pseudomonas (Candida) In summary, both the IDSA and EAU guidelines recognise the increasing prevalence of TMP/SMX resistance and its clinical ramifications, most notably the decreasing utility of TMP/SMX for empiric therapy of UTIs and, therefore, the increasing need for alternate first-line therapies (i.e. fluoroquinolones). Taking into account the low levels of uropathogen resistance to ciprofloxacin (and other fluoroquinolones) and the high bacteriologic potency of this class of agents, the wider use of fluoroquinolones can be expected to translate into more favourable clinical and bacteriologic outcomes. 4. Improving clinical and bacteriologic success in management of UTI: additional considerations Although pathogen resistance is clearly an important consideration in the management of UTIs, other parameters, such as compliance with therapy, can also significantly influence treatment outcomes. Poor patient adherence to treatment, resulting from side effects and/or inconvenient regimens, often leads to sub-therapeutic antibiotic concentrations at sites of infection, which can result in prolonged pathogen persistence, clinical failure and/or selection of resistant organisms. The development of a short, convenient, once-daily regimen of a proven antibiotic has thus long remained an important challenge in the management of UTIs. Recent development and approval of extended-release ciprofloxacin represents an important milestone in the treatment of UTI, as the short course of therapy with this once-daily formulation is likely to increase patient adherence to therapy and, thereby, improve patient outcomes. Additionally, the short duration of therapy with extended-release ciprofloxacin effectively reduces the risk for development of resistance and can result in lower overall cost [24,35,36]. 5. Extended-release ciprofloxacin 5.1. Rationale and criteria for development The overall aim of clinical development of extendedrelease ciprofloxacin was to enhance the pharmacokinetic and pharmacodynamic profile achieved with conventional, immediate-release, twice-daily ciprofloxacin, in order to allow more convenient, once-daily dosing, while providing clinical and bacteriologic efficacy at least equivalent to that observed with the conventional, twice-daily regimen. One of the major criteria in the development of extended-release ciprofloxacin was to obtain single-dose systemic exposure, as reflected by the area under the time versus plasma concentration curve (AUC), equivalent to that observed with twice-daily administration of the conventional formulation. Such a formulation would provide an AUC/MIC ratio equivalent to that of immediate-release ciprofloxacin and thereby retain high activity against pathogens associated with UTIs. A second developmental criterion was the achievement of a maximum plasma concentration (C max ) higher than that observed with a corresponding regimen of conventional, twice-daily ciprofloxacin. Attainment of both equivalent AUC and higher C max values was critical, because the bactericidal activity of ciprofloxacin is concentration-dependent, and the AUC/MIC and C max /MIC ratios are the key determinants in this respect [37,38]. Additionally, achievement of targeted AUC/MIC and C max /MIC values may help prevent the development of resistance [39]. In order to preserve
6 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 S59 the good tolerability and safety profile established for the conventional, immediate-release ciprofloxacin bid, it was essential that the C max with extended-release ciprofloxacin does not exceed the safety threshold established with the 750 mg bid regimen of immediate-release ciprofloxacin. At the same time, it was important to reduce temporal and inter-patient variability in pharmacokinetic parameters versus the conventional, immediate-release ciprofloxacin bid to maintain therapeutic drug concentrations over time and across individual patients. Because previous studies with conventional ciprofloxacin have demonstrated that the attainment of therapeutic drug concentrations requires absorption in the upper gastrointestinal tract (absorption window), as opposed to the distal GI tract (e.g. jejunum, ileum, colon) [40], a major goal in development of extended-release ciprofloxacin was that the drug should primarily be absorbed in the absorption window Absorption The extended-release ciprofloxacin tablet is composed of a bilayer matrix containing two different salts of ciprofloxacin. It is important to stress that extended-release ciprofloxacin does not provide two pulses of immediate drug release (i.e. it is not a staggered-dose delivery system). Instead, oral administration of the tablet results in the immediate release of 35% of the total dose, providing a rapid onset of action, and the remaining 65% of the dose is released within 3 h, allowing complete drug absorption in the upper GI tract. A population kinetic analysis demonstrated reduced absorption variability with extended-release ciprofloxacin (coefficient of variation: 29.5% versus 78.8% with immediate-release ciprofloxacin) [41], indicating that this dosage form has an improved pharmaceutical quality, which may enhance its therapeutic profile. It is important to emphasise that extended-release ciprofloxacin tablets should never be crushed prior to ingestion, because this action may significantly alter drug absorption and, therefore, can dramatically impact the pharmacokinetic and clinical/bacteriologic profile of this formulation Pharmacokinetic and pharmacodynamic parameters The pharmacokinetic properties of extended-release ciprofloxacin (Table 3) indicate that the developmental goals discussed earlier were achieved [42 45]. In particu- lar, AUC values with extended-release ciprofloxacin (500 and 1000 mg qd) are equivalent to those achieved with conventional, immediate-release ciprofloxacin (250 and 500 mg bid), whereas the C max values with extended-release ciprofloxacin (500 and 1000 mg qd) are % higher than those obtained with standard immediate-release ciprofloxacin (250 and 500 mg bid) [43,44]. Additionally, reduced absorption variability with extended-release ciprofloxacin translates into lower variation in peak plasma levels of the drug [41]. Lower pharmacokinetic variability contributes to the fact that the C max value achieved after treatment with 1000 mg qd extended-release ciprofloxacin does not exceed the peak plasma concentrations attained with 750 mg bid immediate-release ciprofloxacin, which have been established to represent a safety ceiling for the use of oral ciprofloxacin. In contrast, maximal plasma concentrations achieved after simultaneous administration of two 500 mg tablets of the immediate-release formulation exceed this safety threshold. Therefore, the pharmacokinetic profile of extended-release ciprofloxacin (500 and 1000 mg qd) is superior to that of conventional, immediate-release ciprofloxacin (250 and 500 mg bid). The pharmacokinetics of extended-release ciprofloxacin 500 and 1000 mg qd is dose-linear, with AUC and C max values being approximately twice as high with the 1000 mg qd dose (Table 3) [42 44]. Importantly, extended-release ciprofloxacin does not exhibit sustained drug release, and there is no accumulation of the drug with repeated dosing [43,44]. Pharmacokinetic parameters of extended-release ciprofloxacin are not significantly affected by ingestion of food [45], indicating that this therapy can be administered either with or without food. The primary route of ciprofloxacin elimination (for both the extended-release and immediate-release formulations) is renal, with approximately one-third of the total dose excreted in the urine as unmodified ciprofloxacin [42]. Steady-state urinary drug concentrations after administration of extended-release ciprofloxacin 500 and 1000 mg qd far exceed the MIC 90 values for common urinary pathogens over the entire 24 h dosing interval (Fig. 1) [43,44]. Additionally, drug concentrations in the urine after therapy with extended-release ciprofloxacin 500 mg qd are substantially higher than those achieved with conventional, immediate-release ciprofloxacin 250 mg bid during the first 12 h, both on days 1 and 5 (Fig. 2) [42 44,46,47]. Table 3 Pharmacokinetic properties of once-daily extended-release ciprofloxacin and twice-daily immediate-release ciprofloxacin [42] C max (mg/l) AUC 0 24 h (mg h/l) T 1/2 (h) T max (h) Extended-release ciprofloxacin 500 mg qd 1.59 ± ± ± ( ) Immediate-release ciprofloxacin 250 mg bid 1.14 ± ± ± ( ) Extended-release ciprofloxacin 1000 mg qd 3.11 ± ± ± (1 4) Immediate-release ciprofloxacin 500 mg bid 2.06 ± ± ± ( ) Values are expressed as mean ± standard deviation (S.D.); T max is expressed as median and range. C max : maximum plasma concentration; AUC 0 24 h : area under concentration versus time curve during 24 h after dosing; T 1/2 : elimination time constant; T max : time to C max.
7 S60 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 Fig. 1. Urinary drug concentrations at steady-state following administration of extended-release ciprofloxacin 500 and 1000 mg qd [43,44] are far greater than the minimal inhibitory concentration (MIC 90 ) values for common urinary pathogens, which are taken from Sahm et al. [46] and Woodcock et al. [47]. Furthermore, pharmacokinetic modelling studies indicate that prostatic drug concentrations following treatment with 1000 mg qd extended-release ciprofloxacin are much greater than the MIC 90 values for pathogens most frequently associated with prostatitis, suggesting that this preparation may also be effective in the management of prostatic infections [41]. Superior initial C max values with extended-release ciprofloxacin qd (500 and 1000 mg) may result in more rapid and/or greater bactericidal effect (versus the conventional, immediate-release ciprofloxacin qd (250 and 500 mg)) against common uropathogens. Recent in vitro and in silico pharmacokinetic/pharmacodynamic modelling studies, which showed that the 500 mg qd extended-release ciprofloxacin provides more rapid killing of E. coli (MIC 90 : 0.03 mg/l) than the standard, immediate-release ciprofloxacin 250 mg bid (Fig. 3), are consistent with this hypothesis, and suggest that rapid achievement of Fig. 2. Urinary drug concentrations following treatment with extended-release ciprofloxacin 500 mg qd are much higher than those achieved after treatment with immediate-release ciprofloxacin 250 mg bid during the first 12 h. The concentrations attained with both formulations are far greater than the minimal inhibitory concentration (MIC 90 ) values for most common urinary pathogens over the entire 24 h (12 h for the 250 mg bid) dosing interval, both at days 1 and 5 [44]. The MIC 90 values for ciprofloxacin are taken from Sahm et al. [46] and Woodcock et al. [47].
8 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 S61 Fig. 3. In vitro and in silico pharmacokinetic/pharmacodynamic (PK/PD) modelling studies indicate that extended-release ciprofloxacin 500 mg qd provides more rapid killing of E. coli (MIC 90 : 0.03 mg/l) than the conventional, immediate-release ciprofloxacin 250 mg bid [48]. Circles: experimental PK/PD data; solid lines: curve fits obtained from PK/PD data by computer modelling. higher peak plasma concentrations with extended-release ciprofloxacin may translate into clinical benefits [48]. Additionally, higher maximum plasma concentrations achieved with extended-release ciprofloxacin 1000 mg qd (versus the conventional, immediate-release ciprofloxacin 500 mg bid) correlate with a greater bactericidal effect over the 24 h period [48]. Taken together, these findings suggest that the pharmacokinetic advantages of extended-release ciprofloxacin may be associated with improved bacteriologic activity in patients with UTI Clinical experience The clinical efficacy of extended-release ciprofloxacin has been documented in studies involving patients with uncomplicated UTIs (500 mg qd) [24,49], as well as in a trial of patients with complicated UTIs or acute pyelonephritis (1000 mg qd) [50]. Results of these studies indicate that extended-release ciprofloxacin is at least as effective as conventional, immediate-release ciprofloxacin (250 and 500 mg bid, respectively) in the treatment of these infections. Fig. 4. Clinical and bacteriologic efficacy of extended-release ciprofloxacin 500 mg qd and conventional, immediate-release ciprofloxacin 250 mg bid in women with uncomplicated urinary tract infections [24].
9 S62 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 Fig. 5. Eradication of various bacterial pathogens with extended-release ciprofloxacin 500 mg qd and conventional, immediate-release ciprofloxacin 250 mg bid in women with uncomplicated urinary tract infections [24] Uncomplicated UTI The clinical and bacteriologic efficacy of 3-day therapy with either extended-release ciprofloxacin 500 mg qd or immediate-release ciprofloxacin 250 mg bid was addressed in a randomised, double-blind study of 891 women with uncomplicated UTIs [24]. Clinical and bacteriologic success rates were evaluated at a test-of-cure visit and longer-term follow-up (4 11 and days after completion of therapy, respectively). As shown in Fig. 4, clinical and bacteriologic success rates were consistently higher with extended-release ciprofloxacin 500 mg qd, although the differences did not reach statistical significance [24]. Extended-release ciprofloxacin was highly active against all pathogenic species, and eradication rates with immediate-release ciprofloxacin were comparable (Fig. 5). Importantly, the rates of clinical failure and new infection at long-term follow-up were lower with extended-release ciprofloxacin (5.0 and 1.7%, respectively, versus 7.4 and 4.9%, respec- tively, with immediate-release ciprofloxacin), confirming the clinical and bacteriologic efficacy of extended-release ciprofloxacin 500 mg qd [24]. These results support the use of extended-release ciprofloxacin as at least an equally effective alternative to conventional, immediate-release ciprofloxacin in women with uncomplicated UTIs. The clinical efficacy of short-course (3-day) therapy with extended-release ciprofloxacin 500 mg qd was also corroborated by a large, prospective study in adult women with uncomplicated UTI [49]. This community-based study enrolled 7360 female outpatients with uncomplicated UTI presenting to over 1900 primary care physicians offices in the US, thereby allowing evaluation of the efficacy of extended-release ciprofloxacin 500 mg qd in standard clinical practice. Clinical cure at the end-of-study visit (2 7 days post-therapy) was achieved in 91.3% of outpatients, without significant differences in outcomes in various subgroups defined by age, race, or educational status [49]. Fig. 6. Clinical and bacteriologic efficacy of extended-release ciprofloxacin 1000 mg qd and conventional, immediate-release ciprofloxacin 500 mg bid in men and women with complicated urinary tract infections or acute pyelonephritis [50].
10 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 S63 Fig. 7. Bacterial eradication at a test-of-cure visit (5 11 days) with extended-release ciprofloxacin 1000 mg qd and conventional, immediate-release ciprofloxacin 500 mg bid in men and women with complicated urinary tract infections or acute pyelonephritis [50]. Slightly lower bacteriologic success rate with extended-release ciprofloxacin 1000 mg qd in patients with acute pyelonephritis can be attributed to development of new infections in three patients; the original pathogen was completely eradicated in two of these three patients [50] Complicated UTI and acute uncomplicated pyelonephritis Clinical and bacteriologic efficacy of 7 14-day therapy with extended-release ciprofloxacin 1000 mg qd versus conventional, immediate-release ciprofloxacin 500 mg bid in patients presenting with complicated UTI or acute pyelonephritis was evaluated in a large (N = 435 men and women) multi-centre, double-blind, randomised study [50]. Clinical cure and bacteriologic eradication rates were higher in patients receiving extended-release ciprofloxacin at both the test-of-cure visit (5 11 days) and late follow-up (28 42 days) (Fig. 6), although the differences were not statistically significant. Extended-release ciprofloxacin 1000 mg qd exhibited high potency across the full spectrum of bacterial pathogens, and conventional, immediate-release ciprofloxacin 500 mg bid showed similar efficacy [50]. Treatment with extended-release ciprofloxacin 1000 mg qd was associated with high rates of bacteriologic eradication at a test-of-cure visit in patients with complicated UTI, as well as in those presenting with acute pyelonephritis (Fig. 7), whereas immediate-release ciprofloxacin was slightly less effective in patients with complicated UTI (Fig. 7) [50]. At late follow-up (28 42 days), extended-release ciprofloxacin 1000 mg qd was associated with reduced rates of clinical failure, new infection and persistent infection (Fig. 8) [50]. Collectively, these findings demonstrate that, in patients with complicated UTI or acute pyelonephritis, extended-release ciprofloxacin 1000 mg qd provides clinical and bacteriologic efficacy comparable to that observed with immediate-release ciprofloxacin 500 mg bid, with a dosing schedule that may facilitate greater patient adherence to therapy. Therefore, extended-release ciprofloxacin 1000 mg qd represents a useful and more convenient treatment Fig. 8. Clinical failure, new infection, and bacterial persistence at late follow-up (28 42 days) after treatment with extended-release ciprofloxacin 1000 mg qd and conventional, immediate-release ciprofloxacin 500 mg bid in men and women with complicated urinary tract infections or acute pyelonephritis [50]. alternative to conventional ciprofloxacin in the management of these infections Safety and tolerability Conventional ciprofloxacin has established an excellent record for tolerability and safety in patients with a wide spectrum of bacterial infections [13,51]. Results from a comparison of immediate-release ciprofloxacin versus TMP/SMX in women with acute pyelonephritis indicate lower rates of digestive or central nervous system adverse events with ciprofloxacin [20]. Clinical studies of extended-release ciprofloxacin described earlier indicate that its safety and tolerability are comparable to those of the conventional formulation. In women with uncomplicated UTIs, treatment-emergent adverse events, regardless of cause, were reported in 27.3% of patients who received extended-release ciprofloxacin 500 mg qd and in 23.5% of those treated with the immediaterelease 250 mg bid formulation [24]. The respective rates for treatment-related adverse events were 10.4 and 9.2% (Table 4) [24]. Most adverse events were mild or moderate in severity, and there were no serious treatment-related adverse events in either group. Only two women in each group discontinued treatment prematurely due to adverse events [24]. Good tolerability of extended-release ciprofloxacin (500 mg qd) was also confirmed in a large study that included over 7000 women with uncomplicated UTI [49]. Treatment was discontinued due to adverse events (primarily gastrointestinal disturbances and rash/urticaria) in <1% of patients, and the incidence of treatment-emergent
11 S64 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 Table 4 Adverse events in patients with uncomplicated UTI, complicated UTI, or acute pyelonephritis treated with extended-release ciprofloxacin or conventional ciprofloxacin [24,50] Uncomplicated UTI Complicated UTI or acute pyelonephritis Extended-release ciprofloxacin 500 mg qd (n = 444) Immediate-release ciprofloxacin 250 mg bid (n = 447) Extended-release ciprofloxacin (n = 517) Nausea 12 (3) 4 (<1) 15 (3) 15 (3) Vaginal moniliasis 4 (<1) 10 (2) 9 (2) 7 (1) Headache 7 (2) 3 (<1) 7 (1) 8 (2) Diarrhoea 12 (2) 7 (1) Dizziness 9 (2) 3 (<1) Vaginitis 4 (<1) 7 (2) Values given in parentheses are percentages. Immediate-release ciprofloxacin 500 mg bid (n = 518) and drug-related adverse events was low. The majority of adverse events were mild or moderate and the frequency of most individual events was <1% [49]. These results are consistent with the findings from the comparative study discussed earlier and confirm the good tolerability and safety of extended-release ciprofloxacin 500 mg qd. Safety and tolerability results with extended-release ciprofloxacin 1000 mg qd in the study of patients with complicated UTIs or acute pyelonephritis were comparable to those obtained with conventional, immediate-release ciprofloxacin 500 mg bid (Table 4) [50]. Premature discontinuation of therapy due to adverse events occurred in 5% of patients receiving extended-release ciprofloxacin 1000 mg qd and in 4% of those treated with conventional ciprofloxacin 500 mg bid. The most frequently reported adverse event in this trial was nausea (3% in both groups) and the overall incidence of adverse events was low [50] Drug interactions Extended-release ciprofloxacin shares an identical profile of drug interactions with conventional, immediate-release ciprofloxacin bid. Co-administration of extended-release ciprofloxacin with omeprazole, didanosine, sulphacrate and antacids or other products containing di- or trivalent cations (e.g. calcium, magnesium, aluminium, iron, or zinc) reduces absorption of ciprofloxacin [42]. Probenecid modifies renal excretion of ciprofloxacin and may therefore increase its levels in serum [42]. Ciprofloxacin decreases the elimination of caffeine and theophylline, and also prevents the generation of paraxanthine after administration of caffeine [42]. In addition, ciprofloxacin may affect the metabolism of phenytoin, and it may also interact with cyclosporines and glyburide [42], and enhance the action of warfarin. Patients treated concurrently with ciprofloxacin and warfarin should be monitored for coagulation status, because ciprofloxacin may increase the antithrombotic activity of warfarin [42] Dosing considerations in special populations No dose adjustment of extended-release ciprofloxacin (500 and 1000 mg qd) is required in the elderly and patients with stable chronic cirrhosis [42]. In patients with renal impairment (creatinine clearance <30 ml/min), clearance of ciprofloxacin is slightly reduced, and dose adjustment is required for 1000 mg qd extended-release ciprofloxacin (to 500 mg qd extended-release ciprofloxacin), but not for 500 mg qd extended-release ciprofloxacin [42]. 6. Conclusions UTI is a common medical condition that affects millions of women in the USA each year and is associated with significant cost. The previously accepted first-line antimicrobial for uncomplicated UTIs, TMP/SMX, has been used to treat these infections for over 20 years, but increasing resistance among common uropathogens has significantly compromised its clinical and bacteriologic efficacy. The rates of resistance to TMP/SMX among E. coli isolates is over 20% in some areas of the USA and approaches or exceeds 30% in Latin America, Europe and the Middle East. High rates of TMP/SMX resistance in different regions of the world and their clinical implications are recognised as an important therapeutic issue by the most recent guidelines developed by the IDSA and EAU, both of which recommend the use of a fluoroquinolone for treatment of uncomplicated UTIs in regions where resistance to TMP/SMX is over 10%. Ciprofloxacin is a highly potent fluoroquinolone, with excellent bactericidal activity against the Gram-negative pathogens commonly associated with UTIs and welldocumented clinical efficacy in a wide range of infections, including UTI. For these reasons, ciprofloxacin has emerged as an important alternative to TMP/SMX in the management of UTI. Compared with conventional, immediate-release ciprofloxacin bid, recently developed extended-release ciprofloxacin qd achieves equivalent AUC with a single daily dose, and provides urinary drug levels that far exceed the MIC 90 values for the most prevalent urinary pathogens over the entire 24 h period, thereby permitting convenient, once-daily dosing. In addition, higher peak plasma concentrations with extended-release ciprofloxacin (versus conventional, immediate-release ciprofloxacin) translate into an enhanced C max /AUC ratio and a more rapid onset
12 D.A. Talan et al. / International Journal of Antimicrobial Agents 23S1 (2004) S54 S66 S65 of bactericidal action. The results of pharmacokinetic and modelling studies further indicate that extended-release ciprofloxacin may have bactericidal activity superior to that of conventional, immediate-release ciprofloxacin bid. Comparative clinical trials of extended-release ciprofloxacin in patients with uncomplicated UTI and in those with complicated UTIs or acute pyelonephritis have demonstrated clinical and bacteriologic efficacy that is at least equivalent to that of conventional ciprofloxacin, with a similar tolerability and safety profile. These results, along with the convenient once-daily dosing regimen, indicate that the use of extended-release ciprofloxacin may facilitate greater patient compliance with therapy, which can effectively translate into higher rates of clinical and bacteriologic success, while also reducing the spread of TMP/SMX resistance. References [1] Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29: [2] Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113:5S 13S. [3] Gales AC, Jones RN, Gordon KA, et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). J Antimicrob Chemother 2000;45: [4] Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J Urol 2002;168: [5] Foxman B, Barlow R, D Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000;10: [6] Roberts WO. Urinary tract infections and the cost of antimicrobial resistance. A special report. Healthcare Information Programs. Postgrad Med [7] Barnett BJ, Stephens DS. Urinary tract infection: an overview. Am J Med Sci 1997;314: [8] Hooton TM. The current management strategies for communityacquired urinary tract infection. Infect Dis Clin North Am 2003; 17: [9] Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003;349: [10] Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalised patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003;45: [11] Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking resistance in the United States today. The surveillance network. Int J Antimicrob Agents 2002;19: [12] Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46: [13] Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther 1992;14: [14] Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspective. Int J Antimicrob Agents 2000;16:5 15. [15] Naber KG, Bergman B, Bishop MC, et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001;40: [16] Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001;135: [17] Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51: [18] Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003;36: [19] Farrell DJ, Morrissey I, De Rubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003;46: [20] Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. J Am Med Assoc 2000;283: [21] Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 1995;35: [22] McCarty JM, Richard G, Huck W, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med 1999; 106: [23] Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim sulfamethoxazole (TMP SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP SMX-resistant uropathogens. Clin Infect Dis 2002;34: [24] Henry Jr DC, Bettis RB, Riffer E, et al. Comparison of oncedaily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002;24: [25] Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329: [26] Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. J Am Med Assoc 1999;281: [27] Jones RN, Kugler KC, Pfaller MA, Winokur PL. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, Diagn Microbiol Infect Dis 1999;35: [28] Zhanel GG, Karlowsky JA, Harding GK. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000;44: [29] Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECOSENS Project. J Antimicrob Chemother 2003;51: [30] Wright SW, Wrenn KD, Haynes ML. Trimethoprim sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999;14: [31] Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother 2001;47:781 7.
Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border
Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border Yvonne Vasquez, MPH W. Lee Hand, MD Department of Research
More informationhttp://dx.doi.org/10.1016/j.jemermed.2015.06.028 The Journal of Emergency Medicine, Vol. 49, No. 6, pp. 998 1003, 2015 Copyright Ó 2015 Elsevier Inc. Printed in the USA. All rights reserved 0736-4679/$
More informationTHE SENSITIVITY OF PATHOGENS OF COMMUNITY-ACQUIRED URINARY TRACT INFECTIONS IN KARAGANDA Ye. A. Zakharova 1, Chesca Antonella 2, I. S.
THE SENSITIVITY OF PATHOGENS OF COMMUNITY-ACQUIRED URINARY TRACT INFECTIONS IN KARAGANDA Ye. A. Zakharova 1, Chesca Antonella 2, I. S. Azizov 1 1 THE SHARED LABORATORY OF SCIENCE RESERCH CENTER, KARAGANDA
More informationRegional community-acquired urinary tract infections in Israel: diagnosis, pathogens, and antibiotic guidelines adherence: A prospective study
International Journal of Infectious Diseases (2007) 11, 245 250 http://intl.elsevierhealth.com/journals/ijid Regional community-acquired urinary tract infections in Israel: diagnosis, pathogens, and antibiotic
More informationKey words: Urinary tract infection, Antibiotic resistance, E.coli.
Original article MICROBIOLOGICAL STUDY OF URINE ISOLATES IN OUT PATIENTS AND ITS RESISTANCE PATTERN AT A TERTIARY CARE HOSPITAL IN KANPUR. R.Sujatha 1,Deepak S 2, Nidhi P 3, Vaishali S 2, Dilshad K 2 1.
More informationGuidelines for Treatment of Urinary Tract Infections
Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationUncomplicated community-acquired urinary tract
Review Increasing Antimicrobial Resistance and the Management of Uncomplicated Community-Acquired Urinary Tract Infections Kalpana Gupta, MD, MPH; Thomas M. Hooton, MD; and Walter E. Stamm, MD Community-acquired
More informationUTI Dr S Mathijs Department of Pharmacology
UTI Dr S Mathijs Department of Pharmacology Introduction Responsible for > 7 million consultations annually 15% of all antibiotic prescriptions 40% of all hospital acquired infections Significant burden
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 10.0 DECEMBER 1997 CLINICAL AND ECONOMIC CONSIDERATIONS IN THE USE OF FLUOROQUINOLONES based primarily on the Technical Report: An Analysis of the Use of Fluoroquinolones
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationSingle-Dose and Three-Day Regimens of Ofloxacin versus Trimethoprim-Sulfamethoxazole for Acute Cystitis in Women
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1991, P. 1479-1483 0066-4804/91/071479-05$02.00/0 Copyright 1991, American Society for Microbiology Vol. 35, No. 7 Single-Dose and Three-Day Regimens of Ofloxacin
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationInternational Journal of Infectious Diseases
International Journal of Infectious Diseases 14 (2010) e770 e774 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Increasing
More informationMultiple drug resistance pattern in Urinary Tract Infection patients in Aligarh
Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh Author(s): Asad U Khan and Mohd S Zaman Vol. 17, No. 3 (2006-09 - 2006-12) Biomedical Research 2006; 17 (3): 179-181 Asad
More informationCork and Kerry SARI Newsletter; Vol. 2 (2), December 2006
Cork and SARI Newsletter; Vol. 2 (2), December 6 Item Type Newsletter Authors Murray, Deirdre;O'Connor, Nuala;Condon, Rosalind Download date 31/1/18 15:27:31 Link to Item http://hdl.handle.net/1147/67296
More informationURINARY TRACT infections
National Patterns in the Treatment of Urinary Tract Infections in Women by Ambulatory Care Physicians Elbert S. Huang, MD, MPH; Randall S. Stafford, MD, PhD ORIGINAL INVESTIGATION Background: Trimethoprim-sulfamethoxazole
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationIDSA GUIDELINES EXECUTIVE SUMMARY
IDSA GUIDELINES International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More information1 Carle Foundation Hospital, Urbana, IL, USA. 2 University of Illinois College of Medicine, Urbana, IL, USA
588822CPJXXX10.1177/0009922815588822Clinical PediatricsAhmed et al research-article2015 Article First-Line Antimicrobial Resistance Patterns of Escherichia coli in Children With Urinary Tract Infection
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationCipro for klebsiella uti
Cipro for klebsiella uti Search Can UTI be an effective treatment for Klebsiella Pneumoniae? It is safe or dangerous to use UTI while suffering from Klebsiella Pneumoniae? 87 discussions on Treato. instock
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationAcute Uncomplicated Cystitis in an Era of Increasing Antibiotic Resistance: A Proposed Approach to Empirical Therapy
VIEWPOINTS Acute Uncomplicated Cystitis in an Era of Increasing Antibiotic Resistance: A Proposed Approach to Empirical Therapy Thomas M. Hooton, 1 Richard Besser, 2 Betsy Foxman, 3 Thomas R. Fritsche,
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationTitle: Antibacterial resistances in uncomplicated urinary tract infections in women: ECO * SENS II data from primary health care in Austria
Author's response to reviews Title: Antibacterial resistances in uncomplicated urinary tract infections in women: ECO * SENS II data from primary health care in Austria Authors: Gustav Kamenski (kamenski@aon.at)
More informationCritical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationCopy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL
SYRINGE LABEL PRESCRIPTION ANIMAL REMEDY FOR ANIMAL TREATMENT ONLY VibraVet* 100 PASTE For Cats and Dogs 100 mg/g DOXYCYCLINE as monohydrate Infopest Verified Antibiotic READ LEAFLET BEFORE USE 2.5 g 2.0
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationDr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust
Dr Eleri Davies Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust Antimicrobial stewardship What is it? Why is it important? Treatment and management of catheter-associated
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationORIGINAL ARTICLE. Uropathogen antibiotic resistance in adult women presenting to family physicians with acute uncomplicated cystitis
ORIGINAL ARTICLE Uropathogen antibiotic resistance in adult women presenting to family physicians with acute uncomplicated cystitis Warren J McIsaac MD MSc CCFP, Tony Mazzulli MD FRCPC, Rahim Moineddin
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationA Study on Urinary Tract Infection Pathogen Profile and Their In Vitro Susceptibility to Antimicrobial Agents
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/65 A Study on Urinary Tract Infection Pathogen Profile and Their In Vitro Susceptibility to Antimicrobial Agents M
More informationWhy fosfomycin trometamol as first line therapy for uncomplicated UTI?
International Journal of Antimicrobial Agents 22 (2003) S79/S83 www.ischemo.org Why fosfomycin trometamol as first line therapy for uncomplicated UTI? G.C. Schito * Microbiology Section, Di.S.C.A.T. Department,
More informationResistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua
Chapter 2 Resistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua A.J. Matute a, E. Hak b, C.A.M. Schurink c, A. McArthur d, E. Alonso e, M. Paniagua e, E. van Asbeck c, A.M.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationProtocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland
Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol
More informationUrinary Tract Infection: Study of Microbiological Profile and its Antibiotic Susceptibility Pattern
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 592-597 http://www.ijcmas.com Original Research Article Urinary Tract Infection: Study of
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More informationURINARY TRACT INFECTION TREATMENT IN COMMUNITY PRACTICE. Clinical Assistant Professor School of Pharmacy LIU
URINARY TRACT INFECTION TREATMENT IN COMMUNITY PRACTICE Jihan Sf Safwan, Pharm.D. Clinical Assistant Professor School of Pharmacy LIU LEARNING OBJECTIVES Identify patients with uncomplicated cystitis (UC)
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationSummary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotab 50 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance Enrofloxacin
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationPharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections
International Journal of Antimicrobial Agents 28S (2006) S35 S41 Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections Teresita
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More informationAntimicrobial practice. Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice
Journal of Antimicrobial Chemotherapy (2003) 51, 379 384 DOI: 10.1093/jac/dkg032 Advance Access publication 6 January 2003 Antimicrobial practice Laboratory antibiotic susceptibility reporting and antibiotic
More informationBest Practice Guidelines for Treatment of Uncomplicated UTIs in Women While Decreasing Risk of Antibiotic Resistance
The Henderson Repository is a free resource of the Honor Society of Nursing, Sigma Theta Tau International. It is dedicated to the dissemination of nursing research, researchrelated, and evidence-based
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.202 Original Research Article Profile of
More informationOriginal Article INTRODUCTION
Original Article ISSN 2465-8243(Print) / ISSN: 2465-8510(Online) https://doi.org/10.14777/uti.2017.12.1.28 Urogenit Tract Infect 2017;12(1):28-34 http://crossmark.crossref.org/dialog/?doi=10.14777/uti.2017.12.1.28&domain=pdf&date_stamp=2017-04-25
More informationSystemic Antimicrobial Prophylaxis Issues
Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationAn Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?
An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? Dr. Andrew Morris Antimicrobial Stewardship ProgramMt. Sinai Hospital University Health Network amorris@mtsinai.on.ca andrew.morris@uhn.ca
More informationAcute pyelonephritis in emergency medicine ward: a four years retrospective review
Hong Kong Journal of Emergency Medicine Acute pyelonephritis in emergency medicine ward: a four years retrospective review TWT Chan, SK Lam, HT Fung Objective: To study the characteristics of patients
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationPHARMA SCIENCE MONITOR
PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES A STUDY ON PRESCRIPTION PATTERN OF ANTIBIOTICS FOR URINARY TRACT INFECTIONS IN SHIMOGA DISTRICT OF KARNATAKA Ramoji Alla *, I.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationClinical and Economic Impact of Urinary Tract Infections Caused by Escherichia coli Resistant Isolates
Clinical and Economic Impact of Urinary Tract Infections Caused by Escherichia coli Resistant Isolates Katia A. ISKANDAR Pharm.D, MHS, AMES, PhD candidate Disclosure Katia A. ISKANDAR declare to meeting
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationABSTRACT ORIGINAL RESEARCH. Gunnar Kahlmeter. Jenny Åhman. Erika Matuschek
Infect Dis Ther (2015) 4:417 423 DOI 10.1007/s40121-015-0095-5 ORIGINAL RESEARCH Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationDistinguishing between complicated and uncomplicated UTI is important because the duration of antimicrobial therapy is typically longer in complicated
CONCISE REVIEW FOR CLINICIANS TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS Treatment of Uncomplicated Urinary Tract Infections in an Era of Increasing Antimicrobial Resistance LOREN G. MILLER, MD,
More information48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections.
48 th Annual Meeting IDWeek and ICAAC: The Cliffs Notes Version Yanina Pasikhova Pharm.D., BCPS-AQ ID, AAHIVP Infectious Diseases Pharmacist Moffitt Cancer Center Navigating the Oceans of Opportunity Skin
More information